Radiopharm Theranostics Raises Radiopharm Ventures Stake From 75% To 87.5% With Lead B7H3 Candidate Betabart Advancing Toward First Patient Dosing In Q1 2026
Benzinga Newsdesk 10 months ago
News
Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance
- Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics
- Leading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026
- First clinical trial globally targeting B7H3 with a systemic radiopharmaceutical
- Two additional preclinical Radiopharm Ventures' assets show early positive results with plans to move to final candidate selection in 2026